FDA review of ANKTIVA combination puts ImmunityBio in focus

ImmunityBio (IBRX) is back on investors’ radar after the US Food and Drug Administration accepted for review a supplemental Biologics License Application for ANKTIVA plus BCG in certain bladder cancer patients.

The filing, supported by additional scientific data, seeks to expand ANKTIVA’s approved use. The company is also outlining potential cost savings for the ANKTIVA and BCG combination compared with other treatment options.

Against this regulatory backdrop, ImmunityBio’s share price has been volatile, with a 1-day share price return of 1.12% and year-to-date share price return of 258.91%. The 1-year total shareholder return stands at 123.77%, while the 5-year total shareholder return is down 49.23%.

If this kind of move has your attention, it could be a good moment to see what else is setting the pace in healthcare AI by scanning 39 healthcare AI stocks

With ImmunityBio’s share price very strong this year, a value score of 3, and the stock trading at about a 20% discount to the US$13.00 analyst target and intrinsic estimates, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 46.3% Undervalued

ImmunityBio’s most followed narrative pegs fair value at $13.50, well above the last close at $7.25, which puts a spotlight on what is driving that gap.

The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.

Read the complete narrative. Read the complete narrative.

Want to understand why this fair value sits well above today’s price? The story leans heavily on sharp revenue expansion, rising margins and a richer earnings multiple. Curious which specific growth and profitability assumptions have the biggest impact on that $13.50 figure? The full narrative lays out those drivers in detail.

Result: Fair Value of $13.50 (UNDERVALUED)

However, this story can shift quickly if ANKTIVA trials outside bladder cancer underperform expectations or if regulators delay or restrict approvals in new indications.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

After considering all of this, are you leaning bullish or cautious on ImmunityBio? Take a closer look at the full picture and weigh both sides by checking the 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If you are serious about sharpening your portfolio, do not stop at one stock. Use focused stock lists to spot opportunities before the crowd does.

• Target reliable income by scanning companies that show up as 9 dividend fortresses and see which ones match your yield and stability goals.
• Hunt for quality at a reasonable price by reviewing the 46 high quality undervalued stocks that pair solid fundamentals with attractive pricing.
• Prioritise peace of mind by checking 63 resilient stocks with low risk scores and focus on stocks that score well on resilience and risk control.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.